Supernus Pharmaceuticals (NASDAQ:SUPN) Sets New 1-Year Low - Here's Why

Key Points

• Supernus Pharmaceuticals shares plunged to a new 52-week low of $29.00, down from the previous close of $41.92, amid increasingly negative analyst sentiment. MarketBeat lists an average “Reduce” rating and a $62.33 average price target.
• The company’s latest quarterly results fell short of expectations, with adjusted earnings of $0.35 per share versus the $0.49 consensus estimate and revenue of $208.6 million versus $217.56 million expected, despite 18% year-over-year revenue growth.
• Supernus announced a substantial $8.13 special dividend for shareholders of record October 30, payable November 6, while the company continues developing and marketing treatments for epilepsy, ADHD, migraines and other neurological conditions.

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) hit a new 52-week low on Tuesday. The stock traded as low as $29.00 and last traded at $29.00, with a volume of 24,865 shares changing hands. The stock had previously closed at $41.92.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on SUPN shares. Zacks Research downgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research note on Monday, October 5th. Weiss Ratings lowered Supernus Pharmaceuticals from a "sell (d+)" rating to a "sell (d-)" rating in a research report on Friday. Wall Street Zen lowered shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. Finally, Cantor Fitzgerald raised their target price on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an "overweight" rating in a research report on Thursday, July 9th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Supernus Pharmaceuticals currently has an average rating of "Reduce" and an average target price of $62.33.

Supernus Pharmaceuticals Stock Performance

The business's fifty day moving average price is $42.42 and its 200-day moving average price is $47.27. The stock has a market cap of $1.75 billion, a PE ratio of -39.01, a P/E/G ratio of 1.21 and a beta of 0.55.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The specialty pharmaceutical company reported $0.35 earnings per share for the quarter, missing the consensus estimate of $0.49 by ($0.14). The company had revenue of $208.60 million for the quarter, compared to analysts' expectations of $217.56 million. Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The firm's revenue for the quarter was up 18.0% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.80) earnings per share. Analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.79 earnings per share for the current fiscal year.

Supernus Pharmaceuticals Dividend Announcement

The business also recently announced a special dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 30th will be given a $8.13 dividend.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of SUPN. Public Employees Retirement System of Ohio bought a new stake in Supernus Pharmaceuticals during the second quarter valued at approximately $25,000. Rockefeller Capital Management L.P. boosted its stake in shares of Supernus Pharmaceuticals by 354.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company's stock worth $42,000 after acquiring an additional 660 shares during the last quarter. Heritage Family Offices LLP purchased a new position in shares of Supernus Pharmaceuticals during the 3rd quarter worth $39,000. Global Retirement Partners LLC purchased a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth $64,000. Finally, Versant Capital Management Inc grew its position in shares of Supernus Pharmaceuticals by 47.2% during the 3rd quarter. Versant Capital Management Inc now owns 1,503 shares of the specialty pharmaceutical company's stock valued at $65,000 after acquiring an additional 482 shares during the period.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company's activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus' marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.